|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, C-GFPSpark tag||CG90265-ACG|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, C-OFPSpark / RFP tag||CG90265-ACR|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, C-Flag tag||CG90265-CF|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, C-His tag||CG90265-CH|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, C-Myc tag||CG90265-CM|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, C-HA tag||CG90265-CY|
|Cynomolgus monkey IL2RA Gene cDNA clone plasmid||CG90265-G|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, N-Flag tag||CG90265-NF|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, N-His tag||CG90265-NH|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, N-Myc tag||CG90265-NM|
|Cynomolgus monkey IL2RA ORF mammalian expression plasmid, N-HA tag||CG90265-NY|
|Cynomolgus monkey IL2RA natural ORF mammalian expression plasmid||CG90265-UT|
|Learn more about expression Vectors|
CD25 (alpha-chain of IL-2 receptor, or IL2RA), is a type I transmembrane glycoprotein with a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic domain. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling. The IL2RA (CD25) gene is a substantial component of the high-affinity receptor molecule highly expressed by activated T lymphocytes. Recently, a strong evidence was obtained for the involvement of IL-2RA in conferring susceptibility to type 1 diabetes (T1D). Cancer growth and development is associated with the stimulation of the innate immune system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and its shedding into the circulation in a soluble form of sIL-2Ralpha. In most haematological malignancies, including different types of leukaemias and lymphomas, sIL-2Ralpha has been found to be released directly from the surface of neoplastic cells thus reflecting the tumour bulk, turnover and activity. Several studies have proved that not only lymphoid cancer cells, but also some non-lymphoid cancer cells, express IL-2R on their surface. They include malignant melanoma and carcinomas of the kidney, head and neck, oesophagus and lung. Thus, sIL-2Ralpha is elevated in most proliferative disturbances of the hematopoietic system and in many solid tumors.